Cytek Biosciences (CTKB) director adds 1,454 shares through RSU vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cytek Biosciences director Michael Holder reported a routine equity compensation event. He acquired 1,454 shares of common stock on May 18, 2026 through the exercise or conversion of restricted stock units, with no open-market purchase or sale involved.
After this transaction, he directly holds 16,721 shares of common stock and 9,457 restricted stock units. The RSU award vests in multiple tranches between August 18, 2024 and August 18, 2025, gradually converting into common shares over time.
Positive
- None.
Negative
- None.
Insider Trade Summary
1,454 shares exercised/converted
Mixed
2 txns
Insider
Holder Michael
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,454 | $0.00 | -- |
| Exercise | Common Stock | 1,454 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 9,457 shares (Direct, null);
Common Stock — 16,721 shares (Direct, null)
Footnotes (1)
- Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. 2/36 of the total shares subject to the RSU Award shall vest on August 18, 2024; 3/36 of the total shares subject to the RSU Award shall vest on November 18, 2024 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award shall vest on March 10, 2025 and each March 10 thereafter; 2/36 of the total shares underlying the RSU Award vesting shall vest on May 18, 2025 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award shall vest on August 18, 2025 and each August 18 thereafter, until fully vested.
Key Figures
Common shares acquired: 1,454 shares
Common shares held after: 16,721 shares
RSUs converted: 1,454 units
+2 more
5 metrics
Common shares acquired
1,454 shares
Common Stock from RSU exercise on May 18, 2026
Common shares held after
16,721 shares
Total direct common stock holdings following transaction
RSUs converted
1,454 units
Restricted Stock Units exercised into common stock on May 18, 2026
RSUs remaining
9,457 units
Restricted Stock Units held after the transaction
Exercise price per share
$0.00 per unit
Reported transaction and conversion price for RSU exercise
Key Terms
Restricted Stock Units, RSU Award, derivative security, vest, +1 more
5 terms
Restricted Stock Units financial
"security_title": "Restricted Stock Units""
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSU Award financial
"Each Restricted Stock Unit (the "RSU Award") represents a contingent right"
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vest financial
"shares subject to the RSU Award shall vest on August 18, 2024"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
contingent right financial
"represents a contingent right to receive one share of the Issuer's common stock"
FAQ
What insider transaction did Cytek Biosciences (CTKB) director Michael Holder report?
Director Michael Holder reported acquiring 1,454 Cytek Biosciences common shares through the exercise or conversion of restricted stock units. This was a compensation-related equity event rather than an open-market purchase or sale of existing shares.
Was Michael Holder’s Cytek Biosciences (CTKB) transaction an open-market buy or sell?
The transaction was not an open-market buy or sell. It reflects the exercise or conversion of 1,454 restricted stock units into common shares, a routine compensation-related equity event with no reported market purchase price or sale proceeds.
What are the key terms of Michael Holder’s RSU award at Cytek Biosciences (CTKB)?
Each restricted stock unit represents a contingent right to receive one Cytek Biosciences common share. The award vests in scheduled tranches on specific dates between August 18, 2024 and August 18, 2025, until the entire grant is fully vested.
Does Michael Holder still have unvested equity at Cytek Biosciences (CTKB) after this transaction?
Yes. Following the conversion of 1,454 RSUs into common stock, Michael Holder still holds 9,457 restricted stock units. These remaining RSUs are expected to vest in future scheduled tranches according to the award’s vesting schedule.